Mangalam Drugs

{
  "main_header": {
    "sid": 138636,
    "name": "Mangalam Drugs",
    "stock_name": "Mangalam Drugs",
    "full_name": "Mangalam Drugs and Organics Ltd",
    "name_url": "stocks-analysis/mangalam-drugs",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "29.41",
    "chg": -1.1,
    "chgp": "-3.61%",
    "dir": -1,
    "prev_price": "30.51",
    "mcapval": "47.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532637,
    "symbol": "MANGALAM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE584F01014",
    "curr_date": "May 22",
    "curr_time": "",
    "bse_nse_vol": "32.49 k",
    "exc_status": "Active",
    "traded_date": "May 22, 2026",
    "traded_date_str": "2026 05 22",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mangalam-drugs-138636-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Mangalam Drugs and Organics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mangalam-drugs-and-organics-ltd-is-rated-strong-sell-4000798",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MangalamDrugsan_mojoScore_4000798.png",
        "date": "2026-05-20 10:10:21",
        "description": "Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook."
      },
      {
        "title": "Mangalam Drugs and Organics Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mangalam-drugs-and-organics-ltd-hits-lower-circuit-amid-heavy-selling-pressure-3996523",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MangalamDrugsan_stocks_hitting_lower_circuit_3996523.png",
        "date": "2026-05-18 10:00:06",
        "description": "At Rs 28.46, sellers were still queuing — but there were no buyers willing to take the other side. Mangalam Drugs and Organics Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price."
      },
      {
        "title": "Are Mangalam Drugs and Organics Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-mangalam-drugs-and-organics-ltd-latest-results-good-or-bad-3994979",
        "imagepath": "",
        "date": "2026-05-16 19:21:27",
        "description": "The latest financial results for Mangalam Drugs and Organics Ltd reveal significant operational challenges. In Q4 FY26, the company reported net sales of ₹67.29 crores, reflecting a quarter-on-quarter growth of 15.26% from ₹58.38 crores in Q3 FY26. However, this figure represents a year-on-year decline of 7.54%, indicating ongoing demand issues. The net profit for the same quarter was a loss of ₹13.42 crores, marking a substantial deterioration compared to the previous year.\n\nThe operating margin for Q4 FY26 fell to -8.35%, a stark contrast to the positive margin of 13.60% reported in Q4 FY25. This collapse in profitability is further underscored by the operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI), which resulted in a loss of ₹5.62 crores, compared to a profit of ₹9.90 crores in the same quarter last year.\n\nFor the full fiscal year FY25, Mangalam Drugs recorded ..."
      },
      {
        "title": "Mangalam Drugs Q4 FY26: Mounting Losses Signal Deepening Operational Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/mangalam-drugs-q4-fy26-mounting-losses-signal-deepening-operational-crisis-3993422",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MangalamDrugsan_quaterlyResult_3993422.png",
        "date": "2026-05-15 18:00:33",
        "description": "Mangalam Drugs and Organics Ltd. reported a devastating fourth quarter for FY26, with net losses widening to ₹13.42 crores—marking a staggering 22,466.67% year-on-year deterioration from a marginal profit of ₹0.06 crores in Q4 FY25. The micro-cap pharmaceutical company, with a market capitalisation of just ₹48.00 crores, saw its stock languish at ₹30.01 on May 15, down 62.74% over the past year and trading 68.34% below its 52-week high of ₹94.80."
      },
      {
        "title": "When is the next results date for Mangalam Drugs and Organics Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-mangalam-drugs-and-organics-ltd-3980424",
        "imagepath": "",
        "date": "2026-05-07 23:16:40",
        "description": "The next results date for Mangalam Drugs and Organics Ltd is scheduled for 14 May 2026...."
      },
      {
        "title": "Mangalam Drugs and Organics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mangalam-drugs-and-organics-ltd-is-rated-strong-sell-3964269",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MangalamDrugsan_mojoScore_3964269.png",
        "date": "2026-04-27 10:10:25",
        "description": "Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook."
      },
      {
        "title": "Mangalam Drugs and Organics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mangalam-drugs-and-organics-ltd-is-rated-strong-sell-3944648",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MangalamDrugsan_mojoScore_3944648.png",
        "date": "2026-04-13 10:10:14",
        "description": "Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 13 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook."
      },
      {
        "title": "Mangalam Drugs and Organics Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mangalam-drugs-and-organics-ltd-hits-upper-circuit-amid-strong-buying-pressure-3937245",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MangalamDrugsan_stocks_hitting_upper_circuit_3937245.png",
        "date": "2026-04-08 10:00:08",
        "description": "At Rs 31.57, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 4.99% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Mangalam Drugs Gains 2.29%: Circuit Limits Highlight Volatility and Investor Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mangalam-drugs-gains-229-circuit-limits-highlight-volatility-and-investor-sentiment-3933465",
        "imagepath": "",
        "date": "2026-04-05 16:00:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>30 Mar:</strong> Lower circuit hit amid heavy selling pressure (₹27.05)</p>\n                    <p><strong>1 Apr:</strong> Upper circuit hit on strong buying interest (₹28.05)</p>\n                    <p><strong>2 Apr:</strong> Marginal gain with subdued volume (₹29.06)</p>\n                    <p><strong>3 Apr:</strong> Week closes at ₹29.06, up 2.29% vs Sensex down 0.29%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.27.74</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.29.06</div..."
      }
    ],
    "total": 196,
    "sid": "138636",
    "stock_news_url": "https://www.marketsmojo.com/news/mangalam-drugs-and-organics-138636"
  },
  "announcements": [
    {
      "details": "Mangalam Drugs And Organics Limitedalam Drugs And Organics Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Mangalam Drugs And Organics Limited - Reply to Clarification- Financial results",
      "datetime": "09-Dec-2019"
    },
    {
      "details": "Mangalam Drugs And Organics Limitedgs And Organics Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Mangalam Drugs And Organics Limited - Clarification - Financial Results",
      "datetime": "21-Nov-2019"
    },
    {
      "details": "Mangalam Drugs And Organics Limited has informed the Exchange regarding Compliance under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Mangalam Drugs And Organics Limited - Other General Purpose",
      "datetime": "15-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Mangalam Drugs and Organics Ltd has declared <strong>5%</strong> dividend, ex-date: 21 Dec 17",
          "dt": "2017-12-21",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Mangalam Drugs and Organics Ltd is Rated Strong Sell

2026-05-20 10:10:21

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Read full news article

Mangalam Drugs and Organics Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight

2026-05-18 10:00:06

At Rs 28.46, sellers were still queuing — but there were no buyers willing to take the other side. Mangalam Drugs and Organics Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price.

Read full news article

Are Mangalam Drugs and Organics Ltd latest results good or bad?

2026-05-16 19:21:27

The latest financial results for Mangalam Drugs and Organics Ltd reveal significant operational challenges. In Q4 FY26, the company reported net sales of ₹67.29 crores, reflecting a quarter-on-quarter growth of 15.26% from ₹58.38 crores in Q3 FY26. However, this figure represents a year-on-year decline of 7.54%, indicating ongoing demand issues. The net profit for the same quarter was a loss of ₹13.42 crores, marking a substantial deterioration compared to the previous year. The operating margin for Q4 FY26 fell to -8.35%, a stark contrast to the positive margin of 13.60% reported in Q4 FY25. This collapse in profitability is further underscored by the operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI), which resulted in a loss of ₹5.62 crores, compared to a profit of ₹9.90 crores in the same quarter last year. For the full fiscal year FY25, Mangalam Drugs recorded ...

Read full news article

Mangalam Drugs Q4 FY26: Mounting Losses Signal Deepening Operational Crisis

2026-05-15 18:00:33

Mangalam Drugs and Organics Ltd. reported a devastating fourth quarter for FY26, with net losses widening to ₹13.42 crores—marking a staggering 22,466.67% year-on-year deterioration from a marginal profit of ₹0.06 crores in Q4 FY25. The micro-cap pharmaceutical company, with a market capitalisation of just ₹48.00 crores, saw its stock languish at ₹30.01 on May 15, down 62.74% over the past year and trading 68.34% below its 52-week high of ₹94.80.

Read full news article

When is the next results date for Mangalam Drugs and Organics Ltd?

2026-05-07 23:16:40

The next results date for Mangalam Drugs and Organics Ltd is scheduled for 14 May 2026....

Read full news article

Mangalam Drugs and Organics Ltd is Rated Strong Sell

2026-04-27 10:10:25

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Read full news article

Mangalam Drugs and Organics Ltd is Rated Strong Sell

2026-04-13 10:10:14

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 13 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Read full news article

Mangalam Drugs and Organics Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent

2026-04-08 10:00:08

At Rs 31.57, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 4.99% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Mangalam Drugs Gains 2.29%: Circuit Limits Highlight Volatility and Investor Sentiment

2026-04-05 16:00:42

Key Events This Week

30 Mar: Lower circuit hit amid heavy selling pressure (₹27.05)

1 Apr: Upper circuit hit on strong buying interest (₹28.05)

2 Apr: Marginal gain with subdued volume (₹29.06)

3 Apr: Week closes at ₹29.06, up 2.29% vs Sensex down 0.29%

Week Open

Rs.27.74

Week Close

Rs.29.06Read full news article

View All News